From: MDM2 SNP309, gene-gene interaction, and tumor susceptibility: an updated meta-analysis
MDM2 309T > G | P53 72Arg > Pro | Case | Control | OR (95% CI) |
---|---|---|---|---|
TT | Arg/Arg | 469 | 762 | Reference |
TT | Arg/Pro | 457 | 791 | 1.09 (0.74-1.61) |
TT | Pro/Pro | 139 | 201 | 1.38 (0.92-2.06) |
TG | Arg/Arg | 646 | 1015 | 1.32 (0.88-1.98) |
TG | Arg/Pro | 785 | 1048 | 1.51 (0.96-2.38) |
TG | Pro/Pro | 304 | 349 | 1.88 (1.26-2.81)* |
GG | Arg/Arg | 307 | 348 | 1.96 (1.01-3.78)* |
GG | Arg/Pro | 339 | 446 | 1.53 (0.92-2.53) |
GG | Pro/Pro | 198 | 108 | 3.38 (1.77-6.47)* |